7.

SDG GOAL 7 – AFFORDABLE AND CLEAN ENERGY

Ensure access to affordable, reliable, sustainable and modern energy for all

Decreasing our carbon footprint

Sanofi has taken the initiative to achieve a 20% reduction in the combined scope 1 and scope 2 CO2
emissions for industrial and R&D sites and sales force vehicles. To reach this goal, Sanofi has formed
strategic partnerships with energy sector leaders, implemented renewable energy projects at our sites
in India, and continued our vehicle policy, including the increase in eco-driving sessions. From 2010 to
2014, the fuel consumption by medical sales teams decreased by 22.3%. Sanofi also gives priority to
shipping medicines by rail and water. In 2014, Sanofi made 86% of its intercontinental shipments by
sea compared to an average of 28% for other health companies. Maritime transport emits 30 times
less CO2 than air transport, which represents 260,000 tons of CO2 saved per year by Sanofi thanks to
shipping by sea.

Partners: -

Links/sources: -

Other SDG Goals addressed: -

Goal 6: Water & Sanitation

We have robust controls in place to manage the risk of pharmaceuticals – and particularly antibiotics – entering the
environment through our waste water pollution and we work with supply chain partners to audit compliance and share
best practice across our industry on managing environmental discharges. We audit our sites looking for ways to reduce
our water usage and aim to cut total water use at each site with high water risk areas by 30% by 2030.
4. SDG GOAL 4 – QUALITY EDUCATION

Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all

e-diabete

Sanofi is a partner of the e-diabete project. The e-diabete health professional training program is
managed with the Université numérique francophone mondiale (UNFM), Senghor University and the
Réseau en Afrique francophone pour la télémédecine (RAFT). In 2016, it was available in 13 African
countries through the use of low-speed internet. Each month, around 1,000 participants may attend
an interactive session presented by local and international experts. Participation in the
teleconferences is increasingly expanded to include not only diabetologists but also internists, nurses,
cardiologists, surgeons and other healthcare professionals. The goal is to have all healthcare
professionals aligned when providing primary care to diabetic patients, in order to improve early
diagnosis and reduce the risk of related complications and premature deaths. In 2016, there were also
48,500 connections on the e-diabete website to consult training materials.

Partners: The Université numérique francophone mondiale (UNFM), Senghor University and the
Réseau en Afrique francophone pour la télémédecine (RAFT)

Links/sources: Brochure Sanofi and Africa “A Sustained Commitment to Serving Patients,” accessible
from: http://en.sanofi.com/csr/download_center/download_center.aspx

Other SDG Goals addressed: SDG Goal 8 – Decent work and economic growth
 Our contribution to the Sustainable Development Goals

As a science-led healthcare company Goal 3, Good Health & Wellbeing, is where we can make the
most important contribution. The goal is underpinned by targets that cover a wide range of health
issues from maternal and child health, to TB, malaria, HIV and environmental health.

Although each of the 17 global goals is focused on a different issue, we believe that health underpins almost
every development theme, each of which enables, or is enabled by, advances in population health.

How we support SDG 3

The primary way in which we support SDG 3 is by using our science and technology to address health needs, and
by making our products affordable and available.

Using our science and technology to address health needs

The biggest impact that we can have on health is to successfully research and develop innovative products.
Through our innovation we aim to develop differentiated, high quality, needed medicines, vaccines and
consumer products to improve health.
We also have a responsibility to impact global health, particularly in the prevention and treatment of infectious
diseases where we have world-leading scientific expertise. We support global efforts to reduce the burden of
HIV/AIDS, HCV,TB, malaria and neglected tropical diseases (NTDs), which disproportionately affect people in
developing countries, through a range of R&D initiatives. In 2018, GSK topped the Access to Medicines Index for
the sixth consecutive time, with specific recognition for having the largest proportion of our R&D pipeline
dedicated to priority diseases.
This work supports SDG 3.31 and 3.B2 in particular. Examples in this area include:

- HIV: Through ViiV Healthcare, we are progressing clinical development programmes for paediatric formulations
of our HIV medicines in partnership with the International Maternal Paediatric Adolescent AIDS Clinical Trials
Network and the Paediatric European Network for Treatment of AIDS.
- TB: We have been working with non-profit scientific organisation Aeras, and with the support of the Bill &
Melinda Gates Foundation, the UK’s Department for International Development and others, to develop a
candidate TB vaccine. We received positive interim results in 2018 for the phase IIb study, and are
continuing the trial with the International AIDS Vaccine Initiative which has recently acquired the TB vaccine
clinical programme from Aeras. We also have a number of promising TB medicines in development.
- NTDs: At our Tres Cantos Open Lab and Vaccines Global Health Institute our scientists research NTDs such
as Chagas disease, leishmaniasis, sleeping sickness and enteric infections. Through our Tres Cantos Open
Lab

1 Target 3.3: By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected
tropical diseases and combat hepatitis, water- borne diseases and other communicable
diseases
2 Target 3.b: Support the research and development of vaccines and medicines for the
communicable and non-communicable diseases that primarily affect developing
countries, provide access to affordable essential medicines and vaccines, in accordance
with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the
right of developing countries to use to the full the provisions in the Agreement on
Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect
public health, and, in particular, provide access to medicines for all
 Foundation – an independent charity – visiting scientists can also work on their own projects to target
diseases disproportionately affecting the developing world, while accessing GSK’s expertise, resources and
capabilities.
In support of SDG 3.D3 we are using our vaccines, medicines and scientific know-how to help the world to better
prepare for future disease outbreaks with pandemic potential and tackle antimicrobial resistance (AMR).
- To prepare for future public health emergencies, we continue to advance rapid-response vaccine platform
technologies and we are collaborating on the development of a universal influenza vaccine candidate.
- We ranked first among the large pharmaceutical companies in the Access to Medicine Foundation’s AMR
Benchmark in 2018 and are committed to researching and developing new vaccines against infections that
will reduce the need for antibiotics even further. For example, we are currently developing vaccines against
RSV (a virus) as well as shigellosis and TB (both caused by bacteria) which are all drivers of current antibiotic
use, and gepotidacin, in our Pharmaceuticals pipeline is potentially the first in a new class of antibiotics.
Making our products affordable and available
We aim to improve the health of millions of people each year by making our products available at responsible
prices that are sustainable for our business. In developing countries, we use innovative pricing structures as part
of our access strategies to extend product reach and in developed markets, we apply a value-based approach to
balance reward for innovation with access and affordability.
We also work in partnership with NGOs, donor organisations, governments and the WHO to broaden access to
medicines, vaccines and other important health interventions in developing countries.

3 Target3.d: Strengthen the capacity of all countries, in particular developing countries, for early
warning, risk reduction and management of national and global health risks
4 Target 3.8: Achieve universal health coverage, including financial risk protection, access to quality
essential health-care services and access to safe, effective, quality and affordable essential medicines
and vaccines for all
5 Target 3.c: Substantially increase health financing and the recruitment, development, training and
retention of the health workforce in developing countries, especially in least developed countries and small
island developing States

Published March 2019

GSK contributes to a number of the SDGs beyond SDG 3. Here we outline some key examples of our work that
further supports the development goals:

Goal 1: No Poverty
As a global healthcare company, our biggest contribution to support those in vulnerable
situations such as humanitarian disasters, is through product donations of our medicines and
vaccines, distributed by our partners.

Goal 5: Gender Equality

We aim for over 37% female representation in our senior roles by 2022. We have a programme
to support development and career progression for high-performing female managers, recruit
and support women early in their careers and report progress on the proportion of women in
SVP/VP and management level roles. Our female senior executive population is increasing as
long-running programmes to create a strong female pipeline deliver results.

Goal 6: Water & Sanitation

We have robust controls in place to manage the risk of pharmaceuticals – and particularly
antibiotics – entering the environment through our waste water pollution and we work with
supply chain partners to audit compliance and share best practice across our industry on
managing environmental discharges. We audit our sites looking for ways to reduce our water
usage and aim to cut total water use at each site with high water risk areas by 30% by 2030.

Goal 8: Decent Work & Economic Growth

In support of employee health and wellbeing, we have a comprehensive preventive healthcare
package for employees – and their eligible dependents – in every country where we operate.
We have placed a strong focus on improving the effectiveness of our people managers and
ensuring most employees have development plans in place.

Goal 9: Industry, Innovation & Infrastructure

See how we support Goal 3 above for details on our work to research and develop innovative
healthcare products.

Goal 10: Reduced inequalities

We have global disability, gender, ethnicity and LGBT+ councils which drive our diversity agenda
with support from our employee resource groups. We have pledged support for the UN LGBTI
global business standards and signed the Charter for Change at the 2018 UK Government
Department for International Development Global Disability Summit to ensure rights, freedoms,
dignity and inclusion for people with disabilities.
Goal 12: Responsible Consumption & Production
Our goal is for all our waste to be repurposed for beneficial uses by 2030, avoiding harmful
environmental impacts from landfill and keeping materials in circulation for use in new
products. We have initiatives in place to reduce plastic use, increase use of recycled plastic
content and encourage the recycling of plastic components. We are targeting 60% of our
electricity to come from renewable sources by 2030.

Goal 13: Climate Action

By 2030 we aim to reduce our operational carbon emissions (Scope 1 and 2) by 20% and reduce
our value chain carbon emissions (Scope 3) by 25% per £ billion revenue. Scope 1 and 2
emissions are being reduced through ongoing efficiency measures, investment in on-site
generation of renewable energy and a reduction in the number of sites. Our supply chain makes
up the largest share (45%) of our Scope 3 value chain carbon footprint and we run ‘kaizen’
events to improve energy efficiency and recognise achievements through our Supplier
Environmental Sustainability Awards.

Goal 15: Life on Land

We are committed to moving towards deforestation-free sourcing for all key commodities
purchased directly by GSK or indirectly on our behalf, although we recognise this is a challenge
due to the complex nature of our supply chains. To date, we have focused on paper packaging,
palm oil and palm oil derivatives and have developed supplier selection criteria, as well as
sourcing standards in conjunction with the Rainforest Alliance.

Goal 16: Peace, Justice & Strong Institutions

We are committed to upholding the Universal Declaration of Human Rights and the core labour
standards set out by the International Labour Organization. We have assessed our human rights
risks to ensure we are focusing efforts where our business has the greatest potential to impact
people. Every employee and complementary worker is required to complete mandatory annual
training on our Code of Conduct. We have a zero-tolerance approach to bribery and corruption
and a robust enterprise-wide anti-bribery and corruption (ABAC) programme designed to
respond to associated risks. We have a Third-Party Oversight programme to strengthen our
management of risk in the supply chain by driving improvements in our network of third parties.

Goal 17: Partnerships for the Goals

In our R&D organisation we form diverse partnerships across academia, charitable institutions
and tech companies, in pursuit of ground-breaking innovation. Our global health work in
support of SDG3 has been done in partnership with many organisations such as PATH, MMV and
others. We worked with the Rainforest Alliance to establish a sourcing standard for paper
packaging, based on the principles of the Forest Stewardship Council. We believe partnerships
across companies, funders, governments and development NGOs spread risks and draw on each
parties’ unique expertise, offering the best route for global health discoveries to be incentivised,
developed and brought to patients as rapidly as possible.
Developing from Within:

Hikma’s Continuing Education Programme for Employees

Investing in our employees is a fundamental part of our long-term organizational success.. Hikma is in many
ways a learning center where employees are encouraged and empowered to continuously develop their skills
and capabilities to ultimately realize their full potential. Developing the highest level of human capital adds
sustainable value to the organization and to society at large while transforming Hikma into an employer
of choice wherever it operates.
We are committed to developing our leaders from within the organization, and that is the spirit behind our
Continuing Education Programme which was implemented across all locations in 2010.
Through the Programme, high achieving Hikma employees are offered company scholarship opportunities of up to
$70,000 USD for the duration of their studies.
Every year, we accept up to eight employees into the Programme. To date, a total of 54 employees received full
scholarships from Hikma to further improve their capabilities and realize their career goals.

54 Employees Received Scholarship Funding

at Hikma

2 Diplomas

21 Bachelor Degrees

31 Masters Degrees

Our Continuing Education Programme

• Employees are eligible for scholarships of up to
$70,000 USD.
• Every year, Hikma accepts up to eight
employees into the programme.
• Since its launch, Hikma has enabled
54 employees to attain higher
education.
Supporting Education for Our Families:

The Children of Hikma Programme

Hikma is committed to furthering education within the communities that it operates. The Children of Hikma
programme links employee benefits with community benefits by offering exceptional children whose
parents work at Hikma a chance to earn full or partial scholarships. Launched in 2009, the programme supports
children’s ambitions of attending institutions of higher learning. It also supports our goal of remaining a top
employer in our operating countries, one that is responsive to the needs of our employees.
Every year, we offer full scholarships to up to five children of Hikma employees, and up to 25 partial scholarships.
Since the launch of Children of Hikma, more than 40 children have received financial assistance to attend
various colleges and universities.

Children of Hikma Highlights

Providing financial assistance and scholarships to the

Objective children of long-standing Hikma employees located in
Jordan.

Up to 3 Full scholarships offered per year

2009 – 2014
Up to 20 Partial scholarships offered per year

Up to 5 Full scholarships offered per year

2015 – Present
Up to 25 Partial scholarships offered per year

41 children of Hikma employees have

To Date graduated through the Program

Through our Children of Hikma Programme, we are able to improve access to quality education by removing
restrictive barriers faced by many of our employees. This results in enabling our employees and their families to
enjoy higher standards of living and to contribute more productively to their communities.

Our Children of Hikma Program

Adds Value
Promote sustained, inclusive and sustainable economic growth, full and productive employment and
decent work for all

Employees make up our most important asset at Hikma, and we strive to maintain ethical and
inclusive employment policies based on merit and achievement. Our aim is to uphold the highest
standards of health and safety for our employees, and we engage with suppliers to ensure best practices
are applied across our value chain.

Operating Ethically and Supporting Inclusive Employment

At Hikma, we are committed to operating with highest levels of integrity and ethics; and ensuring that
transparency remains at the core of our governance model. Our Code of Conduct is communicated to all
employees, and we maintain anonymous “speak- up” hotlines to empower people to address potential
compliance or corruption issues. Corporate Responsibility at Hikma is governed by the Compliance,
Responsibility and Ethics Committee (CREC), a Board-level committee, which focuses on formalising Hikma’s
strong ethical commitment to business integrity.

Hikma also aligns its activities with multiple international frameworks that safeguard best practice standards in
ethics and anti- corruption.

Anti-Bribery and Corruption: Hikma is a founding member of the World Economic Forum’s Partnering
Against Corruption Initiative (“PACI”), the leading business driven global anti-corruption initiative.

Compliance with the UK Modern Slavery Act (MSA): Hikma is committed to ensuring that modern
slavery in the form of forced or compulsory labour and human trafficking does not take place in any of its
businesses or supply chains across the globe.

Promoting Inclusivity through Employment

In 2016, our team in Portugal collaborated with the Portuguese
Refugee Committee to develop a programme that will train and
employ refugees in Europe. The ongoing refugee crisis in our areas of
operation represent one of the world’s most significant challenges,
one that we are committed to help alleviate. The programme’s
first participant, Amir Hamad, is a Sudanese refugee who arrived
to Portugal through Egypt. After being hired and trained by Hikma,
Amir is now an integrated member of the team and has reunited
with his family in Portugal.
 Ensure healthy lives and promote
well-being for all at all ages

At Hikma, our purpose is to provide high-quality pharmaceutical products in an inclusive and affordable way.
By emphasizing quality and accessibility, we ensure that our products benefit people around the world and
contribute to sustainable development. Through a combination of continuous R&D, new product launches and
strategic partnerships, we remain dedicated to improving global health standards and offering greater well-
being to our communities.

Providing Affordability, Accessibility and Quality to Egypt’s Oncology Sector:

The Launch of our Hikma Specialized Unit

2016 marked the successful launch of our Hikma Specialized unit in Egypt as the country’s only local
manufacturer for oncology products. The state of the art facility offers Egyptians and the wider region
with high quality injectable and oral oncology products, helping us fulfil our vision of delivering
affordability and accessibility to our populations in high need medical areas.

The Hikma Specialized portfolio includes products that address an extensive variety of cancer types
(solid tumors & hematology); including: Breast Cancer - Colorectal Cancer - Lung Cancer – Leukemia –
Multiple Myeloma - Thalassemia and others. Through the facility’s rich pipeline and product portfolio,
we hope to create long-term, sustainable value for patients and healthcare providers in Egypt and the
MENA region as a whole.

Hikma Specialized Improves Access to Affordable Medicine by:

 Leveraging expertise and synergy from across our global network to drive Egypt’s oncology sector –
improving local capabilities to meet rapidly evolving patient needs.

 Creating a robust local platform through which to introduce new generic products that are more

economic for patients and less prone to interruptions in availability.

 Reducing costs for Egypt’s healthcare providers enabling them to offer more affordable treatment to
end user patients
SDG 3: Ensure healthy lives and promote well-being for all at all ages.

We aim to enable people to share in medical progress, regardless of their income or background.

As a Life Science company, health care is an important focus of our business. Based on scientific
findings, we develop innovative products and solutions to improve people’s quality of life through
disease prevention and treatment and to make a responsible contribution to the welfare of society.

To achieve this, we invest significantly each year in researching and developing new pharmaceuticals
and treatments. To offer access to state-of-the-art medication to people in developing countries and
emerging economies with low purchasing power and substandard health systems, we have spent
many years supporting patient programs and collaborating with the World Health Organization
(WHO), international aid agencies, nongovernmental organizations and political decision-makers.

Our current focus lies on the availability of contraceptives and products for fighting neglected
tropical diseases such as Chagas and African sleeping sickness. Our measures always also include
information and training offers.

By 2030, we aim to provide 100 million women in developing countries and emerging economies
with the access to the modern-day contraception that more than 200 million women worldwide
currently lack. This is one way in which we intend to help improve local food supplies and reduce
poverty in rural areas. We also consider this a significant contribution toward reaching the goals set
by the United Nations of empowering women and achieving gender equality (SDG 5).

In addition, Bayer will expand access to everyday health for 100 million people in underserved
communities around the world with an initial focus on women’s health and expanding access to
micronutrients for pregnant women and children.

In general, Bayer is working on adapting its pricing policy towards local purchasing power and
strengthening the patient access programs to increase the availability and affordability of Bayer
products.

00000000000000000000000000000000000000000000000000000000000000000000000000000
Missions of the pharmaceutical industry (preservation of health and innovations in SDGs)

The 17 Sustainable Development Goals balance the three dimensions of sustainable development:
economic, social and environmental. In addition, all of the goals are interlinked and indivisible.
Among them, however, the following agenda is closely related to the pharmaceutical industry. They
are goals and targets toward which R&D-based pharmaceutical companies as members of JPMA
should take the initiative through measures such as further demonstrating their R&D capabilities,
promoting proper use, and improving access to pharmaceuticals.

Excerpt from transforming our world: the 2030 Agenda for Sustainable Development

Declaration

The new Agenda

26.

To promote physical and mental health and well-being, and to extend life expectancy for all, we must
achieve universal health coverage and access to quality health care. No one must be left behind. We
commit to accelerating the progress made to date in reducing newborn, child and maternal mortality
by ending all such preventable deaths before 2030. We are committed to ensuring universal access
to sexual and reproductive health-care services, including for family planning, information and
education. We will equally accelerate the pace of progress made in fighting malaria, HIV/AIDS,
tuberculosis, hepatitis, Ebola and other communicable diseases and epidemics, including by
addressing growing anti-microbial resistance and the problem of unattended diseases affecting
developing countries. We are committed to the prevention and treatment of non-communicable
diseases, including behavioural, developmental and neurological disorders, which constitute a major
challenge for sustainable development.

Goal 3.

Ensure healthy lives and promote well-being for all at all ages

3.3

By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and
combat hepatitis, water-borne diseases and other communicable diseases
3.4

By 2030, reduce by one third premature mortality from non-communicable diseases through
prevention and treatment and promote mental health and wellbeing

3.8

Achieve universal health coverage, including financial risk protection, access to quality essential
health-care services and access to safe, effective, quality and affordable essential medicines and
vaccines for all

3.b

Support the research and development of vaccines and medicines for the communicable and non-
communicable diseases that primarily affect developing countries, provide access to affordable
essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement
and Public Health, which affirms the right of developing countries to use to the full the provisions in
the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to
protect public health, and, in particular, provide access to medicines for all

Goal 9.

Build resilient infrastructure, promote inclusive and sustainable industrialization and foster
innovation

9.1

Develop quality, reliable, sustainable and resilient infrastructure, including regional and transborder
infrastructure, to support economic development and human well-being, with a focus on affordable
and equitable access for all

9.5
Enhance scientific research, upgrade the technological capabilities of industrial sectors in all
countries, in particular developing countries, including, by 2030, encouraging innovation and
substantially increasing the number of research and development workers per 1 million people and
public and private research and development spending

9.b

Support domestic technology development, research and innovation in developing countries,

including by ensuring a conducive policy environment for, inter alia, industrial diversification and
value addition to commodities